Last reviewed · How we verify

NCT01122381

Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine

Terminated Phase 1/Phase 2 Results posted Last updated 11 August 2015
What this trial tests

Phase 1/Phase 2 trial testing ethosuximide in Headache, Migraine in 5 participants. Terminated before completion.

Timeline
1 December 2011
Primary endpoint
1 April 2014
1 April 2014

Quick facts

Lead sponsorUS Department of Veterans Affairs
PhasePhase 1/Phase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment5
Start date1 December 2011
Primary completion1 April 2014
Estimated completion1 April 2014
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

US Department of Veterans Affairs

Who can join

Adults 18 to 65, any sex, with Headache, Migraine. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine whether ethosuximide works better than placebo in the prevention of episodic migraine among veterans.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ethosuximide

Trials testing the same drug.

Other recruiting trials for Headache, Migraine

Currently open trials in the same condition.

Other US Department of Veterans Affairs trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01122381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing